MannKind Corporation
MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.64
Price-0.53%
-$0.03
1Y
Price
Market Cap
$1.732b
Small
Price/Earnings 3y Avg5y Avg
56.4x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+21.8%
EBITDA Margin+9.7%
Net Profit Margin+27.2%
Free Cash Flow Margin+21.8%
EBITDA Margin+9.7%
Net Profit Margin+27.2%
Free Cash Flow MarginRevenue
$313.787m
+9.9%
1y CAGR+50.9%
3y CAGR+46.3%
5y CAGREarnings
$29.233m
+6.0%
1y CAGR+141.1%
3y CAGR+103.9%
5y CAGREPS
$0.10
-
1y CAGR+147.0%
3y CAGR+105.5%
5y CAGRBook Value
-$44.552m
$494.640m
Assets$539.192m
Liabilities$225.951m
DebtDebt to Assets
45.7%
3.1x
Debt to EBITDAFree Cash Flow
$43.235m
+31.7%
1y CAGR+205.2%
3y CAGR+148.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company